Association of polypharmacy and hyperpolypharmacy with frailty states: a systematic review and meta-analysis

PurposeTo investigate: (1) the cross-sectional association between polypharmacy, hyperpolypharmacy and presence of prefrailty or frailty; (2) the risk of incident prefrailty or frailty in persons with polypharmacy, and vice versa.MethodsA systematic review and meta-analysis was performed according t...

Full description

Saved in:
Bibliographic Details
Main Authors: Palmer, Katie (Author) , Pazan, Farhad (Author) , Wehling, Martin (Author)
Format: Article (Journal)
Language:English
Published: 2019
In: European geriatric medicine
Year: 2018, Volume: 10, Issue: 1, Pages: 9-36
ISSN:1878-7657
DOI:10.1007/s41999-018-0124-5
Online Access:Verlag, Volltext: http://dx.doi.org/10.1007/s41999-018-0124-5
Verlag, Volltext: https://doi.org/10.1007/s41999-018-0124-5
Get full text
Author Notes:Katie Palmer, Emanuele R. Villani, Davide L. Vetrano, Antonio Cherubini, Alfonso J. Cruz-Jentoft, Denis Curtin, Michael Denkinger, Marta Gutiérrez-Valencia, Adalsteinn Guðmundsson, Wilma Knol, Diane V. Mak, Denis O’Mahony, Farhad Pazan, Mirko Petrovic, Chakravarthi Rajkumar, Eva Topinkova, Catarina Trevisan, Tischa J.M. van der Cammen, Rob J. van Marum, Martin Wehling, Gijsbertus Ziere, Roberto Bernabei, Graziano Onder, On behalf of the European Geriatric Medicine Society Pharmacology special interest group

MARC

LEADER 00000caa a2200000 c 4500
001 1588207730
003 DE-627
005 20220815114439.0
007 cr uuu---uuuuu
008 190228r20192018xx |||||o 00| ||eng c
024 7 |a 10.1007/s41999-018-0124-5  |2 doi 
035 |a (DE-627)1588207730 
035 |a (DE-576)518207730 
035 |a (DE-599)BSZ518207730 
035 |a (OCoLC)1341040718 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Palmer, Katie  |e VerfasserIn  |0 (DE-588)1179389662  |0 (DE-627)1067053298  |0 (DE-576)518207498  |4 aut 
245 1 0 |a Association of polypharmacy and hyperpolypharmacy with frailty states  |b a systematic review and meta-analysis  |c Katie Palmer, Emanuele R. Villani, Davide L. Vetrano, Antonio Cherubini, Alfonso J. Cruz-Jentoft, Denis Curtin, Michael Denkinger, Marta Gutiérrez-Valencia, Adalsteinn Guðmundsson, Wilma Knol, Diane V. Mak, Denis O’Mahony, Farhad Pazan, Mirko Petrovic, Chakravarthi Rajkumar, Eva Topinkova, Catarina Trevisan, Tischa J.M. van der Cammen, Rob J. van Marum, Martin Wehling, Gijsbertus Ziere, Roberto Bernabei, Graziano Onder, On behalf of the European Geriatric Medicine Society Pharmacology special interest group 
264 1 |c 2019 
300 |a 28 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Published online: 7 November 2018 
500 |a Gesehen am 28.02.2019 
500 |a Composition of European Geriatric Medicine Society special interest group on Pharmacology: Marit Bakken, Jean-Pierre Baeyens, Athanase Benetos, Antonio Cherubini, Peter Crome, Alfonso J. Cruz-Jentoft, Michael Denkinger, Tomas Frühwald, Paul Gallagher, Adalsteinn Guðmundsson, Stephen Jackson, Paul Jansen, Wilma Knol, Denis O’Mahony, Graziano Onder, Desmond O’Neill, Mirko Petrovic, Alberto Pilotto, Elina Ronnemaa, Jens-Ulrik Rosholm, José Antonio Serra, George Soulis, Tischa JM van der Cammen, Nathalie van der Velde, Rob van Marum, Martin Wehling, Gijsbertus Ziere 
520 |a PurposeTo investigate: (1) the cross-sectional association between polypharmacy, hyperpolypharmacy and presence of prefrailty or frailty; (2) the risk of incident prefrailty or frailty in persons with polypharmacy, and vice versa.MethodsA systematic review and meta-analysis was performed according to PRISMA guidelines. We searched PubMed, Web of Science, and Embase from 01/01/1998 to 5/2/2018. Pooled estimates were obtained through random effect models and Mantel-Haenszel weighting. Homogeneity was assessed with the I2 statistic and publication bias with Egger’s and Begg’s tests.ResultsThirty-seven studies were included. The pooled proportion of polypharmacy in persons with prefrailty and frailty was 47% (95% CI 33-61) and 59% (95% CI 42-76), respectively. Increased odds ratio of polypharmacy were seen for prefrail (pooled OR = 1.52; 95% CI 1.32-1.79) and frail persons (pooled OR = 2.62, 95% CI 1.81-3.79). Hyperpolypharmacy was also increased in prefrail (OR = 1.95; 95% CI 1.41-2.70) and frail (OR = 6.57; 95% CI 9.57-10.48) persons compared to robust persons. Only seven longitudinal studies reported data on the risk of either incident prefrailty or frailty in persons with baseline polypharmacy. A significant higher odds of developing prefrailty was found in robust persons with polypharmacy (pooled OR = 1.30; 95% CI 1.12-1.51). We found no papers investigating polypharmacy incidence in persons with prefrailty/frailty.ConclusionsPolypharmacy is common in prefrail and frail persons, and these individuals are also more likely to be on extreme drug regimens, i.e. hyperpolypharmacy, than robust older persons. More research is needed to investigate the causal relationship between polypharmacy and frailty syndromes, thereby identifying ways to jointly reduce drug burden and prefrailty/frailty in these individuals.Prospero registration numberCRD42018104756. 
534 |c 2018 
650 4 |a Ageing 
650 4 |a Drugs 
650 4 |a Frail 
650 4 |a Hyperpolypharmacy 
650 4 |a Medications 
650 4 |a Polypharmacy 
650 4 |a Prefrail 
700 1 |a Pazan, Farhad  |d 1980-  |e VerfasserIn  |0 (DE-588)116216302X  |0 (DE-627)102561416X  |0 (DE-576)507240219  |4 aut 
700 1 |a Wehling, Martin  |d 1957-  |e VerfasserIn  |0 (DE-588)129939331  |0 (DE-627)484463152  |0 (DE-576)297912577  |4 aut 
773 0 8 |i Enthalten in  |t European geriatric medicine  |d [Cham] : Springer International Publishing, 2010  |g 10(2019), 1, Seite 9-36  |h Online-Ressource  |w (DE-627)627611737  |w (DE-600)2556794-9  |w (DE-576)32440008X  |x 1878-7657  |7 nnas  |a Association of polypharmacy and hyperpolypharmacy with frailty states a systematic review and meta-analysis 
773 1 8 |g volume:10  |g year:2019  |g number:1  |g pages:9-36  |g extent:28  |a Association of polypharmacy and hyperpolypharmacy with frailty states a systematic review and meta-analysis 
856 4 0 |u http://dx.doi.org/10.1007/s41999-018-0124-5  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://doi.org/10.1007/s41999-018-0124-5  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190228 
993 |a Article 
994 |a 2019 
998 |g 129939331  |a Wehling, Martin  |m 129939331:Wehling, Martin  |d 60000  |d 65400  |e 60000PW129939331  |e 65400PW129939331  |k 0/60000/  |k 1/60000/65400/  |p 20 
998 |g 116216302X  |a Pazan, Farhad  |m 116216302X:Pazan, Farhad  |d 60000  |d 65400  |e 60000PP116216302X  |e 65400PP116216302X  |k 0/60000/  |k 1/60000/65400/  |p 13 
999 |a KXP-PPN1588207730  |e 3056980747 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"eki":["1588207730"],"doi":["10.1007/s41999-018-0124-5"]},"name":{"displayForm":["Katie Palmer, Emanuele R. Villani, Davide L. Vetrano, Antonio Cherubini, Alfonso J. Cruz-Jentoft, Denis Curtin, Michael Denkinger, Marta Gutiérrez-Valencia, Adalsteinn Guðmundsson, Wilma Knol, Diane V. Mak, Denis O’Mahony, Farhad Pazan, Mirko Petrovic, Chakravarthi Rajkumar, Eva Topinkova, Catarina Trevisan, Tischa J.M. van der Cammen, Rob J. van Marum, Martin Wehling, Gijsbertus Ziere, Roberto Bernabei, Graziano Onder, On behalf of the European Geriatric Medicine Society Pharmacology special interest group"]},"physDesc":[{"extent":"28 S."}],"recId":"1588207730","note":["Published online: 7 November 2018","Gesehen am 28.02.2019","Composition of European Geriatric Medicine Society special interest group on Pharmacology: Marit Bakken, Jean-Pierre Baeyens, Athanase Benetos, Antonio Cherubini, Peter Crome, Alfonso J. Cruz-Jentoft, Michael Denkinger, Tomas Frühwald, Paul Gallagher, Adalsteinn Guðmundsson, Stephen Jackson, Paul Jansen, Wilma Knol, Denis O’Mahony, Graziano Onder, Desmond O’Neill, Mirko Petrovic, Alberto Pilotto, Elina Ronnemaa, Jens-Ulrik Rosholm, José Antonio Serra, George Soulis, Tischa JM van der Cammen, Nathalie van der Velde, Rob van Marum, Martin Wehling, Gijsbertus Ziere"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"title":[{"title":"Association of polypharmacy and hyperpolypharmacy with frailty states","title_sort":"Association of polypharmacy and hyperpolypharmacy with frailty states","subtitle":"a systematic review and meta-analysis"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"627611737","disp":"Association of polypharmacy and hyperpolypharmacy with frailty states a systematic review and meta-analysisEuropean geriatric medicine","origin":[{"dateIssuedKey":"2018","publisherPlace":"[Cham] ; Paris","dateIssuedDisp":"2018-","publisher":"Springer International Publishing ; Elsevier Masson"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"note":["Erscheint sechsmal jährlich","Gesehen am 27.05.2020"],"title":[{"title_sort":"European geriatric medicine","title":"European geriatric medicine","subtitle":"EGM"}],"titleAlt":[{"title":"EGM"}],"pubHistory":["1.2010 -"],"id":{"zdb":["2556794-9"],"issn":["1878-7657"],"eki":["627611737"]},"part":{"year":"2019","volume":"10","pages":"9-36","extent":"28","text":"10(2019), 1, Seite 9-36","issue":"1"}}],"person":[{"display":"Palmer, Katie","family":"Palmer","given":"Katie","role":"aut"},{"family":"Pazan","given":"Farhad","role":"aut","display":"Pazan, Farhad"},{"display":"Wehling, Martin","family":"Wehling","role":"aut","given":"Martin"}],"origin":[{"dateIssuedDisp":"2019","dateIssuedKey":"2019"}]} 
SRT |a PALMERKATIASSOCIATIO2019